License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition

The following table summarizes revenues by collaboration, category of revenue, and the method of recognition (in thousands):

			Year Ended December 31,
Revenues recognized:	Over time	Point in time	2021		2020		2019
Gilead license to domvanalimab		*	$	328,838	$	-	$	-
Gilead license to zimberelimab		*		-		55,096		-
Development services for all Gilead programs	*			1,135		-		-
Gilead access rights related to the    Company's research and    development pipeline	*			30,909		15,421		-
Taiho license to domvanalimab		*		15,000		-		-
Taiho license to zimberelimab		*		-		-		8,000
Taiho access rights	*			7,000		7,000		7,000
Total collaboration and license revenues			$	382,882	$	77,517	$	15,000

Summary of Revenue Recognized as a Result of Changes in Deferred Revenue

The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

	Year Ended December 31,
Revenue recognized in the period from:	2021		2020		2019
Amounts included in deferred revenue    at the beginning of the period	$	202,082	$	7,000	$	7,000
Performance obligations satisfied in a    previous period		-		-		-

Schedule of Payments Allocated to Performance Obligations

At the amendment closing date, the Company allocated the transaction price to the new and remaining performance obligations identified as follows:

			Amount
Allocation of transaction price
Deferred revenues as of 12/21/2021			$	165,086
Option payment for Domvanalimab				275,000
Option payment for Etrumadenant				250,000
Option payment for Quemliclustat				200,000
Total transaction price allocated to performance obligations			$	890,086
Allocation to performance obligations	Distinct	Combined	Amount
Domvanalimab license	*		$	328,838
Etrumadenant license and R&D activities		*		218,722
Quemliclustat license and R&D activities		*		175,618
Domvanalimab R&D activities	*			34,528
Zimberelimab R&D and commercial services	*			11,243
Access rights related to the Company's research and development pipeline	*			84,076
Material rights to option continuation periods	*			37,061
Total			$	890,086

Gilead and Taiho

Summary of Revenues

The following table summarizes the revenues recognized from the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho) (in thousands):

	Year Ended December 31,
	2021		2020		2019
License revenue	$	343,838	$	55,096	$	8,000
License and development services revenue		1,135		-		-
Other collaboration revenue		37,909		22,421		7,000
Total collaboration and license revenues	$	382,882	$	77,517	$	15,000